These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28399017)

  • 1. Iron-induced hypophosphatemia: an emerging complication.
    Zoller H; Schaefer B; Glodny B
    Curr Opin Nephrol Hypertens; 2017 Jul; 26(4):266-275. PubMed ID: 28399017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
    Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
    J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.
    Schaefer B; Tobiasch M; Wagner S; Glodny B; Tilg H; Wolf M; Zoller H
    Bone; 2022 Jan; 154():116202. PubMed ID: 34534708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
    Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
    Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophosphatemia related to intravenous iron therapy with ferric carboxymaltose: A case series.
    Seng NW; Barco JB; Wong MH; Lim KX; Peh WM; Ng CT; Cushway T; Foo FJ; Koh FH
    Transfus Med; 2023 Dec; 33(6):503-508. PubMed ID: 37263781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].
    Lecoq AL; Dong C; Carbonnel F; Becquemont L
    Therapie; 2021; 76(6):705-714. PubMed ID: 33962799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia.
    Schouten BJ; Doogue MP; Soule SG; Hunt PJ
    Ann Clin Biochem; 2009 Mar; 46(Pt 2):167-9. PubMed ID: 19151167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
    Glaspy JA; Wolf M; Strauss WE
    Adv Ther; 2021 Jul; 38(7):3531-3549. PubMed ID: 34053011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.
    Schouten BJ; Hunt PJ; Livesey JH; Frampton CM; Soule SG
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2332-7. PubMed ID: 19366850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report.
    Samões B; Silva B; Martins A; Oliveira D; Rajão Martins F; Fonseca D; Costa L; Bernardes M
    Joint Bone Spine; 2023 Sep; 90(5):105586. PubMed ID: 37127260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose.
    Fang W; McMahon LP; Bloom S; Garg M
    JGH Open; 2019 Oct; 3(5):438-440. PubMed ID: 31633052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia following intravenous iron suppletion].
    Koks N; Donga E; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.
    Blumenstein I; Shanbhag S; Langguth P; Kalra PA; Zoller H; Lim W
    Expert Opin Drug Saf; 2021 Jul; 20(7):757-769. PubMed ID: 33993818
    [No Abstract]   [Full Text] [Related]  

  • 17. Parenteral iron therapy and phosphorus homeostasis: A review.
    Kalantar-Zadeh K; Ganz T; Trumbo H; Seid MH; Goodnough LT; Levine MA
    Am J Hematol; 2021 May; 96(5):606-616. PubMed ID: 33471363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of hypophosphatemia induced by intravenous administration of saccharated iron oxide].
    Konjiki O; Fukaya S; Kanou H; Imamura T; Iwamoto T; Takasaki M
    Nihon Ronen Igakkai Zasshi; 1994 Oct; 31(10):805-10. PubMed ID: 7853746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bone and Nutrition. The relationship between iron and phosphate metabolism].
    Takashi Y; Fukumoto S
    Clin Calcium; 2015 Jul; 25(7):1037-42. PubMed ID: 26119317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.